恒瑞医药：子公司收到SHR-1905注射液药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-1905 injection, a monoclonal antibody targeting TSLP, which aims to improve inflammation and control disease progression [1] Group 1: Company Developments - Heng Rui Medicine (600276.SH) announced that its subsidiary, Guangdong Heng Rui Medicine Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration for SHR-1905 injection [1] - The SHR-1905 injection is designed to block the release of inflammatory cytokines and inhibit downstream inflammatory signaling [1] Group 2: Market Context - There is a similar product, Tezepelumab (AstraZeneca/Amgen, marketed as Tezspire), which has been approved and is projected to generate approximately $1.22 billion in global sales in 2024 according to EvaluatePharma database [1]